Meeting
2018 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Results from the NIVOREN GETUG-AFU 26 study.
Authors
Laurence Albiges
Gustave Roussy Institute of Oncology, University of Paris-Sud, Villejuif, France
Laurence Albiges , Sylvie Negrier , Cécile Dalban , Gwenaelle Gravis , Christine Chevreau , Stephane Oudard , Brigitte Laguerre , Philippe Barthelemy , Delphine Borchiellini , Marine Gross-Goupil , Lionnel Geoffrois , Meryem Brihoum , Bernard Escudier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Clinical Trial Registration Number
NCT03013335
Citation
J Clin Oncol 36, 2018 (suppl 6S; abstr 577)
DOI
10.1200/JCO.2018.36.6_suppl.577
Abstract #
577
Poster Bd #
E14
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Safety and efficacy of nivolumab in metastatic renal cell carcinoma (mRCC): Final analysis from the NIVOREN GETUG AFU 26 study.
First Author: Laurence Albiges
Poster
2019 ASCO Annual Meeting
Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
First Author: Matthew R. Zibelman
Poster
2018 ASCO Annual Meeting
Effectiveness and safety of pazopanib (PAZO) and everolimus (EVE) in a changing treatment (Tx) landscape: Interim results of the non-interventional study PAZOREAL.
First Author: Martin Boegemann
Poster
2024 ASCO Gastrointestinal Cancers Symposium
First-line FOLFOX therapy for advanced esophageal squamous cell carcinoma: Multicenter prospective study in Japan.
First Author: Kunihiro Fushiki